Faced with rocky interim data for rare disease drug, Aeglea lays off more staff and seeks exit route

Employees at Aeglea BioTherapeutics who survived the company’s previous two rounds of layoffs may be left wondering whether it was worth it, as the biotech effectively throws in the towel in response to the latest data from one of its two remaining rare disease candidates.